Navigation Links
QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lilly's Investigational Cancer Compounds
Date:11/18/2013

HILDEN, Germany, and GERMANTOWN, Maryland, November 18, 2013 /PRNewswire/ --


  • Collaboration aims to use QIAGEN's companion diagnostic development capabilities to create a companion diagnostic paired with a novel oncology compound from Lilly
  • New partnership builds on Lilly-QIAGEN framework agreement for development of advanced diagnostic tests to guide treatment with innovative therapies
  • Third project follows success of FDA-approved therascreen  KRAS test in metastatic colorectal cancer and clinical development of JAK2 genetic test in blood cancers

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and Company (NYSE: LLY) to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic information in patient samples to enable personalized decisions on treatments. The latest collaboration, involving an undisclosed Lilly compound and an undisclosed molecular diagnostic target, builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year.

QIAGEN and Lilly are long-standing partners in personalized healthcare. QIAGEN's therascreen® KRAS RGQ PCR Kit has been widely adopted by laboratories since its July 2012 approval by the Food and Drug Administration (FDA) as a companion diagnostic. The therascreen KRAS Test detects gene mutations in metastatic colorectal
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
2. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
3. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
4. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
5. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
6. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
7. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
8. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
9. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
10. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
11. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2015 ... on the discovery and development of novel cancer immunotherapies, ... , M.D., Ph.D., as Chief Executive Officer and ... Drs. Wong and Ho join an experienced management team ... company: Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... STOCKHOLM , Aug. 31, 2015 Trimb ... an agreement to acquire YouMedical Group BV ("YouMedical"), a ... YouMedical has total annual sales of approximately EUR 16 ... categories. "Our ambition is to build ... an important step toward that goal. YouMedical gives us ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food Processing ... and beverage processors, equipment manufacturers and leaders in the field of academia. ... and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry and ...
(Date:8/31/2015)... Irvine,CA (PRWEB) , ... August 31, 2015 , ... Proove ... Orange County Technology Alliance Annual High Tech Awards. , Now in its 22nd ... and products which drive innovation here, across the nation and around the world. The ...
Breaking Biology Technology:FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... (Amex:,SGN) announced earlier today that breaking news will ... regarding the law firm of Vianale & Vianale, ... a life sciences company focused on the monitoring,detection ... Signalife uses its patented signal technology to design ...
... SAN DIEGO, Sept. 2 Halozyme Therapeutics,Inc. ... developing and,commercializing products targeting the extracellular matrix, ... Vice President,Research, Michael J. LaBarre, PhD, Vice ... President, Legal., "Halozyme is committed to ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... the Company is initiating a U.S.,Phase 2 ... in,combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal,Investigator is Dr. ...
Cached Biology Technology:Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Louis sheds light on one of the most important events ... years ago. No would-be colonizer could have survived on ... major threat for organisms accustomed to soaking in water. ... drying out might be provided by bryophytes, a group that ...
... of Minnesota have found that the hydrodynamic environment of fish ... available on the Journal of Experimental Biology Web ... for Earth-surface Dynamics. Catch a glimpse of a fish,s ... is. Tuna and mackerel look as if they should outpace ...
... the progression of advanced renal cell carcinoma (RCC), a form ... a new study published in the Journal of Clinical ... disease, but the outlook for patients has improved in the ... multiple pathways within cancer cells," study author Dr. Cora N. ...
Cached Biology News:Moss helps chart the conquest of land by plants 2Moss helps chart the conquest of land by plants 3Moss helps chart the conquest of land by plants 4Research finds water movements can shape fish evolution 2Promising results shown for kidney cancer drug 2